{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+Virus",
    "query": {
      "intervention": "Hepatitis A Virus"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 483,
    "total_pages": 49,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+Virus&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T09:49:05.461Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00983060",
      "title": "Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Genotype-1 Relapse"
      ],
      "interventions": [
        {
          "name": "NIM811",
          "type": "DRUG"
        },
        {
          "name": "Placebo BID + SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 59,
      "start_date": "2009-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Orlando, Florida • Sarasota, Florida + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983060"
    },
    {
      "nct_id": "NCT00984620",
      "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon-alpha (IFN)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2009-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 6,
      "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more",
      "locations": [
        {
          "city": "Tulepo",
          "state": "Mississippi"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00984620"
    },
    {
      "nct_id": "NCT03596697",
      "title": "A Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B",
        "Infectious Disease",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "CRV431",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hepion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 92,
      "start_date": "2019-07-09",
      "completion_date": "2021-06-04",
      "has_results": false,
      "last_update_posted_date": "2021-12-01",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 3,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska • San Antonio, Texas",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03596697"
    },
    {
      "nct_id": "NCT04318379",
      "title": "Therapeutic Hepatitis C Virus Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "HCVax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GeneCure Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-20",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04318379"
    },
    {
      "nct_id": "NCT00874770",
      "title": "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2009-06",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 11,
      "location_summary": "Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00874770"
    },
    {
      "nct_id": "NCT03067129",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir Adult Formulation",
          "type": "DRUG"
        },
        {
          "name": "Glecaprevir + Pibrentasvir Pediatric Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2017-03-20",
      "completion_date": "2022-09-12",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03067129"
    },
    {
      "nct_id": "NCT05286879",
      "title": "Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Infectious Disease",
        "Risk Reduction Behavior",
        "Substance Use",
        "Substance Abuse",
        "Stimulant Use Disorder"
      ],
      "interventions": [
        {
          "name": "Patient Navigator",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mobile Health Unit",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 601,
      "start_date": "2022-03-31",
      "completion_date": "2025-12-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Dallas, Texas • Fort Worth, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05286879"
    },
    {
      "nct_id": "NCT07658976",
      "title": "Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection",
        "Sexually Transmitted Infection"
      ],
      "interventions": [
        {
          "name": "HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA",
          "type": "DRUG"
        },
        {
          "name": "STI PEP - Doxycycline as Doxy-PEP",
          "type": "DRUG"
        },
        {
          "name": "3P mHealth package",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Handout about HIV PrEP options available at the site",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard-of-care HIV PrEP counseling from qualified study staff",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "HIV Prevention Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "29 Years",
        "sex": "MALE",
        "summary": "18 Years to 29 Years · Male only"
      },
      "enrollment_count": 400,
      "start_date": "2026-09-01",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • The Bronx, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07658976"
    },
    {
      "nct_id": "NCT06903338",
      "title": "A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Viral Hepatitis"
      ],
      "interventions": [
        {
          "name": "Tobevibart",
          "type": "DRUG"
        },
        {
          "name": "Elebsiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 124,
      "start_date": "2025-03-12",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 13,
      "location_summary": "Chandler, Arizona • Los Angeles, California • Redwood City, California + 8 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06903338"
    },
    {
      "nct_id": "NCT00252538",
      "title": "Genetic and Biochemical Markers of Interferon-Induced Depression.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Depression"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2006-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-09-18T09:49:05.461Z",
      "location_count": 3,
      "location_summary": "Long Beach, California • Minneapolis, Minnesota • Portland, Oregon",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252538"
    }
  ]
}